.
Clinically Proven Procedure Improves the Appearance of Cellulite
DENVER, CO--(Marketwired - Mar 21, 2014) - Ulthera, Inc. , a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications, announced today that it has acquired Cabochon Aesthetics, Inc. (Cabochon), the ninth company started by premier medical device incubator, The Foundry . The FDA-cleared system developed by Cabochon -- used in a procedure to improve the appearance of cellulite -- will allow Ulthera to expand its technology offerings for physician practices worldwide. The minimally invasive procedure targets the tight connective-tissue bands in the underlying structure of cellulite, known as fibrous septae. It uses an innovative precision-guided, vacuum-assisted approach to optimally release the restricting septae, improving the appearance of cellulite and providing a smoother look to the skin. "Doctors tell us that so many of their female patients express frustration over cellulite's unwanted and stubborn dimpling effects," said Matthew Likens, president and CEO of Ulthera. "The procedure developed by Cabochon is a clinically proven solution with reproducible and reliable results. We're confident this technology will address the vast unmet need for a cellulite treatment that is both effective and highly satisfying to patients. "
In Cabochon's pivotal study for FDA clearance, assessment of cellulite severity by an independent physician panel demonstrated that a single procedure significantly improved the appearance of cellulite. CEO of Cabochon, Ben Brian, Ph. D., was enthused about positive patient responses following this procedure. "Patients' appearance satisfaction was zero percent before being treated, and climbed to 69 percent just two weeks after being treated. What's more, after three months, 85 percent of patients were satisfied, and after one year, 94 percent were satisfied. Considering so many women have concluded that cellulite is untreatable -- even with diet and exercise -- these data are very compelling. "
Dr. Brian continued, "Ulthera has a proven track record of successfully commercializing the Ulthera® System -- the first-and-only energy-based device with a non-invasive lift indication -- with more than 2,000 Systems sold worldwide. This, coupled with the Company's dedication to continued clinical advancements, made bringing Cabochon under its wing a natural fit. "
Likens added, "Cabochon and its signature procedure were an ideal addition to Ulthera's portfolio. First and foremost, the technology works, and second, it's a platform that fills a very clear void for our physician customers. The acquisition enhances our ability to bring value to our customers' practices and help drive even more patients through their doors. "
The procedure developed by Cabochon will be discussed at the American Academy of Dermatology's (AAD) Annual Meeting , March 21-25, 2014 in Denver, in the following sessions:
Poster Session: Multicenter Pivotal Study of the Safety and Effectiveness of Controlled Tissue Release for the Treatment of Cellulite
Saturday, March 22, 11:55 AM MT
Presenter: Michael S. Kaminer, MD, FAAD
Scientific Session: Dermatologic Surgery: Cosmetic Tips and Pearls
Sunday, March 23, 2:00 PM - 5:00 PM MT
Speaker: William P. Coleman III, MD, FAAD
The system developed by Cabochon received FDA clearance for short-term improvement in the appearance of cellulite in the buttocks and thighs of adult females, based on three-month pivotal study data. Ulthera plans to launch the product on a limited basis in the latter part of 2014. About Ulthera, Inc.
Ulthera, Inc. is a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications. The company's signature technology is the Ulthera® System, which is the first and only energy-based device that is FDA-cleared for use as an aesthetic treatment -- the Ultherapy® procedure -- that non-invasively lifts the eyebrow and skin on the neck and under the chin. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company. For more information, visit www.ultherapy.com . Contact Information


Ulthera, Inc. Plans to Enter Cellulite Market With Acquisition of Cabochon Aesthetics, Inc

.
Clinically Proven Procedure Improves the Appearance of Cellulite
DENVER, CO--(Marketwired - Mar 21, 2014) - Ulthera, Inc. , a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications, announced today that it has acquired Cabochon Aesthetics, Inc. (Cabochon), the ninth company started by premier medical device incubator, The Foundry . The FDA-cleared system developed by Cabochon -- used in a procedure to improve the appearance of cellulite -- will allow Ulthera to expand its technology offerings for physician practices worldwide. The minimally invasive procedure targets the tight connective-tissue bands in the underlying structure of cellulite, known as fibrous septae. It uses an innovative precision-guided, vacuum-assisted approach to optimally release the restricting septae, improving the appearance of cellulite and providing a smoother look to the skin. "Doctors tell us that so many of their female patients express frustration over cellulite's unwanted and stubborn dimpling effects," said Matthew Likens, president and CEO of Ulthera. "The procedure developed by Cabochon is a clinically proven solution with reproducible and reliable results. We're confident this technology will address the vast unmet need for a cellulite treatment that is both effective and highly satisfying to patients. "
In Cabochon's pivotal study for FDA clearance, assessment of cellulite severity by an independent physician panel demonstrated that a single procedure significantly improved the appearance of cellulite. CEO of Cabochon, Ben Brian, Ph. D., was enthused about positive patient responses following this procedure. "Patients' appearance satisfaction was zero percent before being treated, and climbed to 69 percent just two weeks after being treated. What's more, after three months, 85 percent of patients were satisfied, and after one year, 94 percent were satisfied. Considering so many women have concluded that cellulite is untreatable -- even with diet and exercise -- these data are very compelling. "
Dr. Brian continued, "Ulthera has a proven track record of successfully commercializing the Ulthera® System -- the first-and-only energy-based device with a non-invasive lift indication -- with more than 2,000 Systems sold worldwide. This, coupled with the Company's dedication to continued clinical advancements, made bringing Cabochon under its wing a natural fit. "
Likens added, "Cabochon and its signature procedure were an ideal addition to Ulthera's portfolio. First and foremost, the technology works, and second, it's a platform that fills a very clear void for our physician customers. The acquisition enhances our ability to bring value to our customers' practices and help drive even more patients through their doors. "
The procedure developed by Cabochon will be discussed at the American Academy of Dermatology's (AAD) Annual Meeting , March 21-25, 2014 in Denver, in the following sessions:
Poster Session: Multicenter Pivotal Study of the Safety and Effectiveness of Controlled Tissue Release for the Treatment of Cellulite
Saturday, March 22, 11:55 AM MT
Presenter: Michael S. Kaminer, MD, FAAD
Scientific Session: Dermatologic Surgery: Cosmetic Tips and Pearls
Sunday, March 23, 2:00 PM - 5:00 PM MT
Speaker: William P. Coleman III, MD, FAAD
The system developed by Cabochon received FDA clearance for short-term improvement in the appearance of cellulite in the buttocks and thighs of adult females, based on three-month pivotal study data. Ulthera plans to launch the product on a limited basis in the latter part of 2014. About Ulthera, Inc.
Ulthera, Inc. is a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications. The company's signature technology is the Ulthera® System, which is the first and only energy-based device that is FDA-cleared for use as an aesthetic treatment -- the Ultherapy® procedure -- that non-invasively lifts the eyebrow and skin on the neck and under the chin. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company. For more information, visit www.ultherapy.com . Contact Information

Ulthera, Inc. Plans to Enter Cellulite Market With Acquisition of Cabochon Aesthetics, Inc.

Cabochon Aesthetics

Allay Therapeutics

Cotera

Nuvaira

Forsight VISION5

TWELVE

Transcend Medical

Ardian

Heartport

Devices for Vascular Intervention

Oximetrix

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

Cabochon Aesthetics is developing a minimally invasive medical device for office-based fat removal treatments.

Ulthera

Itamar Medical develops a minimally invasive diagnostic that measures through a finger probe the Peripheral Arterial Tone (PAT) signal. The Itamar device is approved for the diagnosis of sleep apnea and as an indicator of endothelial dysfunction. The company was founded in 1997 and is based in Israel. On December 16th, 2021, Itamar Medical was acquired by ZOLL at a valuation of $538M.

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing our proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. The company believes its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis, or NASH, which is a chronic disease that constitutes a large unmet medical need. NASH is a severe form of Non-Alcoholic Fatty Liver Disease, or NAFLD, which is characterized by inflammation in the liver in addition to the presence of excess liver fat. NASH is often discovered incidentally, often times by elevated liver enzyme levels in blood tests. NASH patients may be asymptomatic or suffer from fatigue, with other symptoms occurring as the liver disease advances. As the disease progresses, persistent fatty infiltration and inflammation cause liver damage marked by fibrosis and the gradual loss of normal liver cells, which dramatically increases the risk of late-stage severe liver diseases, such as cirrhosis, carcinoma and end-stage liver disease, each potentially requiring liver transplantation. In addition to its serious hepatic complications, NASH is also associated with an increased risk of cardiovascular complications, adding to the risks associated with metabolic syndrome. Metabolic syndrome is a serious health condition caused by obesity, physical inactivity and genetic factors that results in a higher risk of cardiovascular disease, diabetes, stroke and NASH. Patients with NASH have an increased overall mortality rate, as compared to control populations, and independent third-party epidemiological studies have shown that such increased mortality is a result of liver-related mortality and a higher risk of cardiovascular disease associated with NASH, independently of the risks associated with metabolic syndrome.

Allen Baharaff

Chief Executive Officer

February 7, 2014 by Brad Perriello
The U.S. Patent & Trademark Office nixes 2 patents at issue in Smith & Nephew's long-running infringement battle with Interlace Medical and subsequent acquirer Hologic. The U.S. Patent & Trademark Office dealt a setback to Smith & Nephew (FTSE: SN , NYSE: SNN ) last month when it invalidated claims in a pair of patents at the core of a long-running infringement dispute with Interlace Medical and its subsequent acquirer, Hologic  (NSDQ: HOLX ). Smith & Nephew sued Interlace in 2010, alleging infringement of a pair of patents with the MyoSure fibroid tumor device, and filed against Hologic after the Interlace buyout in January 2011. Sign up to get our free newsletters delivered right to your inbox. In September 2012, a jury  awarded $4 million in damages  to cover Smith & Nephew's lost profits from the infringement. Further damages, however, can't yet be decided because the jury's verdict was too vague, according to Judge Rya Zobel of the U.S. District Court for Massachusetts. In October 2013, Hologic  asked a federal judge in Massachusetts to revisit that loss . Last June, Judge Rya Zobel of the U.S. District Court for Massachusetts  upheld that decision  but found that any damages owed by Hologic to the British medical products giant couldn't yet be determined.

U.S. Patent Office nixes Smith & Nephew patents in spat with Hologic

Membrane oxygenation on the rise and ready for disruption in Germany
The number of extracorporeal membrane oxygenation (ECMO) procedures in Germany rose to 5,949 in 2014 effectively tripling the number of procedures in five years, reports consultancy firm, assets Consulting Healthcare GmbH. The report is based on observation of OPS codes in Germany that were recently released by the German Institute of Medical Documentation and Information (DIMDI). […]
Real drug or counterfeit? TruTag Technologies reader & edible barcode can tell
TruTag Technologies Inc. had developed an innovative, edible product security solution that addresses the trillion-dollar global counterfeit problem. At a recent event, TruTag Director of Business Development Steven Yoder presented on the latest advancements in security features for food and drug packaging entitled:  “Going Beyond the Package:  What’s Next in Food and Pharmaceutical Security.” TruTag Technologies […]
BeVITAL app connects post-surgical patients and physicians
Wearable biosensor firm Vital Connect, Inc. and start up BePATIENT have released a new system called BeVITAL. The remote patient monitoring solution combines VitalConnect’s FDA-cleared biosensor, HealthPatch MD, with BePATIENT’s web-based solution and associated app, to enable personalized healthcare programs accessible through mobile devices and computers. BeVITAL is designed for patients after they’ve been discharged […]
Collaboration speeds Waters Corp. through new product introduction, brings innovative mass detector to life
In 2013, analytical-instrument manufacturer Waters Corporation set out to develop a cost-effective mass detector that met specific size, usability, and affordability requirements. The detector required an agile development organization and a particular time-to-market window while meeting high quality standards. The detector, called ACQUITY QDa, came from a technically complex project because Waters engineers planned to […]
Rowiak looks to use lasers to treat presbyopia at its source with ‘seeing scalpel’
Rowiak Co. is looking to treat nearsightedness – also known as presbyopia – using a femtosecond laser and optical coherence tomography. Called the “seeing scalpel,” the technology is designed to be customized for treating difference ophthalmological disorders, the company said. Hannover, Germany-based Rowiak spun out of the Laser Zentrum Hannover in 2003. “As experts in […]
Hamilton Thorne’s 2015 profits jump 20%
Profits for Hamilton Thorne (CVE:HTL) jumped 20% last year as the laser maker’s focus on its core markets paid off. The Beverly, Mass., and Toronto-based company, which makes precision laser devices and image analysis systems for the assisted reproductive technologies, regenerative medicine and developmental biology research markets, posted profits of $1.0 million, or 2¢ per […]
CS Medical releases QuikDry TEE probe drying cloth
CREEDMOOR, NORTH CAROLINA – CS Medical announces the release of their newest product designed to aid in the circle of care for TEE probes. The QwikDry TEE Ultrasound Probe Drying Cloth is designed to effectively dry TEE ultrasound probes at the conclusion of high-level disinfection and rinse. The TEE ultrasound probes should be thoroughly dried […]
Atlas Vac Machine offers All Electric medical device tray sealer
Atlas Vac Machine’s lineup of tray sealers now includes an All Electric Sealer — no pneumatics. In seeking the ultimate in precise down-force control, our engineers have replaced the traditional pneumatic press with the next generation of press drive systems. Coupled with the heaviest heater & platen cross section in the industry, electric auto shuttles, […]
UV Disinfection continues to grow in infection control
Ultraviolet Light Disinfection is not a new technology to many industries, but more and more experts are utilizing the technology in the growing concern of providing infection control in hospitals globally. The most recent area of the world to take an interest in using UV in these capacities is Canada. UV disinfection works by utilizing […]
SL Power’s new MU425S AC/DC power supply family improves medical equipment power performance
SL Power Electronics, a division of SL Industries and an industry leader in the design and manufacture of rugged, highly reliable power supplies, today announces its 425 watt, single output MU425 Series AC/DC power supply. This latest offering addresses the complexity and unique power needs of healthcare systems such as surgical equipment, home healthcare therapeutic […]
Newport introduces 2-inch, vertical drive mirror mount for industrial application
Newport Corporation, a worldwide leader in photonic solutions, expands its industry leading portfolio of opto-mechanics with the HVM-2i, a compact and robust vertical drive kinematic mount for 2 inch diameter optics. The HVM-2i features a unique ball-and-wedge drive mechanism that enhances the overall performance of the optical mount by reducing stiction and backlash to negligible […]
Leave a Reply
You must be logged in to post a comment. Need Medtech news in a minute? We Deliver! MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today. Tweets by @MassDevice
Need Medtech news in a minute? We Deliver! MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today. Medical Design & Outsourcing covers the technical advancements in design, development, and contract manufacturing of medical devices and equipment. DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights. Follow us

Hologic asks court to revisit loss to Smith & Nephew over MyoSure device

Hologic says a Massachusetts jury ruled against it in a patent infringement lawsuit, awarding damages of $4 million over the MyoSure device Hologic acquired along with Interlace Medical.
        
        


Legal News, News Well, Patent Infringement, Women&amp;#039;s Healthread more

Hologic loses $4M patent suit to Smith &amp; Nephew over Interlace fibroid tech

Hologic Buys Interlace Medical for $125 Mln
January 11, 2011
Follow @luisarbeltran
Interlace Medical, which was backed by Baird Venture Partners, has been sold to Hologic for $125 million. Additional earn-out payments can take place over the next two years, a statement said. Framingham, Mass.-based Interlace is a medical device company that has developed the MyoSure, which is used to remove intrauterine fibroids and polyps. Interlace received $20.5 million in Series C financing in 2009 from investors including BVP, Spray Venture Partners and New Leaf Venture Partners. Baird Venture Partners is the U.S. VC fund of Baird Private Equity. PRESS RELEASE
Baird Venture Partners (BVP), the U.S.-based venture fund of Baird Private Equity, announced today that Interlace Medical (Interlace), a Baird Venture Partners III portfolio company, has been sold to Hologic for $125 million with additional earn-out payments over the next two years. This acquisition will allow Interlace to accelerate the adoption of its products through the Hologic distribution network. In June 2009, Interlace raised $20.5 million in Series C financing from investors that included BVP, Spray Venture Partners, New Leaf Venture Partners, HLM Venture Partners, Hambrecht & Quist Capital Management LLC, and Aperture Venture Partners. Based in Framingham, Mass., Interlace is a medical device company dedicated to providing novel solutions within the women’s health sector. Interlace developed and commercialized the MyoSure™ system, an easy-to-use, minimally invasive treatment to remove intrauterine fibroids and polyps. Fibroids are a common cause of abnormal uterine bleeding, which afflicts 5 million women in the United States. The MyoSure system’s allows physicians the flexibility to conduct procedures in either an operating room or office setting. “We were able to partner with a great management team at Interlace to develop a much needed product serving the women’s health sector,” said Michael Liang, BVP Partner. “The acquisition of Interlace by Hologic provides a nice early return for our BVP III investors, and further validates our strategy of proactively identifying healthcare companies that are capital efficient and can be an attractive acquisition for trade buyers.”
“Baird Venture Partners has been a great partner for us,” said Bill Gruber, Interlace President and CEO. “Their lead role in our latest financing and active role on the Board accelerated our growth initiatives and ability to get the MyoSure product into the marketplace. Their involvement was invaluable to help us enter our next phase of growth as part of Hologic.”
Baird Venture Partners raised BVP III, a $170 million fund, in 2008. The Fund has made eight investments to date. About Baird Venture Partners
Baird Venture Partners, the U.S.-based venture capital fund of Baird Private Equity, makes venture capital investments in early and expansion stage business services and life sciences companies. Baird Venture Partners leverages its in-depth sector knowledge, experienced investment team and network of relationships to serve as a value-added partner for its portfolio companies. For more information, please visit www.bairdventurepartners.com. About Baird Private Equity
Baird Private Equity, the global private equity group of Robert W. Baird & Co. (Baird), makes venture capital, growth equity and buyout investments in smaller, high potential companies in the United States through Baird Venture Partners and Baird Capital Partners, in China through Baird Capital Partners Asia, and in Europe through Baird Capital Partners Europe. Baird Private Equity has a global team of investment and operations professionals in nine offices across the United States, Europe and Asia, including a team of operating professionals in Asia. Baird Private Equity and its affiliates have raised and managed over $2.7 billion in capital and invested in more than 240 companies since the 1980s. For more information, please visit www.bairdprivateequity.com. © 2015 Buyouts Insider / Argosy Group LLC

Hologic Buys Interlace Medical for $125 Mln

XconomyBoston — 
Bedford, MA-based Hologic, a provider of diagnostics, medical imaging, and surgical products for women, announced today that it has bought Interlace Medical of Framingham, MA, for $125 million in cash. Interlace, which makes a hysteroscopic tissue removal system, will be integrated into Hologic’s (NASDAQ: HOLX ) gynecological surgical products business. The deal also includes two annual contingent payments, which will be a “multiple of the incremental revenue growth over the prior year,” according to the announcement.

Hologic Buys Interlace for $125M

Interlace Medical

Interlace Medical Corporation designs and develops minimally invasive devices for the gynecological surgeon to aid them in removal of uterine fibroids and polyps.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare Cabochon Aesthetics vs Interlace Medical

Customers evaluate the quality of Cabochon Aesthetics's products using the following success metrics.